A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

October 5, 2021 updated by: Bristol-Myers Squibb

A Phase 1, Open-label, Crossover Study to Evaluate the Pharmacokinetics of BMS-986165 Administered as Various Prototypic Solid Tablet Formulations in Healthy Subjects

The purpose of this study is to evaluate the drug levels of BMS-986165 in when taken by mouth as various solid tablet prototypes, by healthy participants.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
56

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
      • Nottingham, United Kingdom, NG11 6JS
        • Quotient Sciences Miami

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • No clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations.
  • Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive, and total body weight ≥50 kg (110 lb). BMI = weight (kg)/(height [m])2 at screening.
  • Willing and able to consume 4 units of alcohol (Part B only)
  • A negative polymerase chain reaction (PCR) test for coronavirus disease 2019 (COVID-19) at screening and admission
  • Males and females must agree to follow specific methods of contraception, if applicable

Exclusion Criteria:

  • Current or recent (within 3 months or 90 days of study drug administration) clinically significant gastrointestinal disease that, in the opinion of the investigator or medical monitor, could impact upon the absorption of study drug
  • Any medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of or active liver disease.
  • Clinically significant history or presence of acute or chronic bacterial, fungal, or viral infection (eg, pneumonia, septicemia) within the 3 months or 90 days prior to screening.

Other protocol-defined inclusion/exclusion criteria apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Part A: Reference Treatment
Drug: Reference Treatment- BMS-986165-01
Specified dose on specified days
Other Names:
  • Deucravacitinib
Experimental: Part A Prototype
Drug: Prototype BMS-986165
Specified dose on specified days
Other Names:
  • Deucravacitinib
Experimental: Part C Reference Treatment
Drug: Reference Treatment- BMS-986165-01
Specified dose on specified days
Other Names:
  • Deucravacitinib
Experimental: Part C: Prototype
Drug: Prototype BMS-986165
Specified dose on specified days
Other Names:
  • Deucravacitinib
Experimental: Part B: Treatment 1
Drug: Prototype BMS-986165
Specified dose on specified days
Other Names:
  • Deucravacitinib
Experimental: Part B: Treatment 2
Drug: Prototype BMS-986165
Specified dose on specified days
Other Names:
  • Deucravacitinib
Experimental: Part B: Treatment 3
Drug: Prototype BMS-986165
Specified dose on specified days
Other Names:
  • Deucravacitinib
Experimental: Part B: Treatment 4
Drug: Famotidine
Specified dose on specified days
Drug: Prototype BMS-986165
Specified dose on specified days
Other Names:
  • Deucravacitinib
Experimental: Part B: Treatment 5
Drug: Prototype BMS-986165
Specified dose on specified days
Other Names:
  • Deucravacitinib
Other: Alcohol
Specified quantity on specified days

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Maximum observed plasma concentration (Cmax) of BMS-986165
Time Frame: Day 1 and Day 7
Day 1 and Day 7
Time of maximum observed plasma concentration (Tmax) of BMS-986165
Time Frame: Day 1 and Day 7
Day 1 and Day 7
Area under the plasma concentration-time curve from time zero to t (AUC (0-t)) of BMS-986165
Time Frame: Day 1 and Day 7
Part A, B, C
Day 1 and Day 7

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Incidence of Nonserious Adverse Events (AEs)
Time Frame: Up to approximately 60 days (for Parts A & C), approximately 69 days (for Part B)
Up to approximately 60 days (for Parts A & C), approximately 69 days (for Part B)
Incidence of Serious Adverse Events (AEs)
Time Frame: Up to approximately 83 days (for Parts A & C), approximately 92 days (for Part B)
Up to approximately 83 days (for Parts A & C), approximately 92 days (for Part B)
Incidence of clinically significant changes in clinical laboratory results: Hematology tests
Time Frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests
Time Frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests
Time Frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Incidence of clinically significant changes in vital signs: Blood pressure
Time Frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Incidence of clinically significant changes in vital signs: Heart rate
Time Frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Incidence of clinically significant changes in vital signs: Respiratory rate
Time Frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Incidence of clinically significant changes in vital signs: Body temperature
Time Frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF
Time Frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave.
Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS
Time Frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization
Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval
Time Frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
The QT interval is the time from the start of the Q wave to the end of the T wave.
Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval
Time Frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)
PR interval is the time from the onset of the P wave to the start of the QRS complex
Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bristol-Myers Squibb

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 10, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 25, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 25, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 28, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 28, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 3, 2020

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 6, 2021

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 5, 2021

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IM011-136

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings